If You Invested in Invech Holdings Inc (IVHI)

Invech Holdings, Inc. (trading under the symbol IVHI) is a Nevada corporation whose common stock is quoted on the OTC Markets. According to its filings with the U.S. Securities and Exchange Commission (SEC), the company has a class of common stock with a par value of $0.001 per share. Invech Holdings, Inc. reports under Commission File Number 000-25553 and is identified by IRS Employer Identification Number 98-0419476.

The company’s principal executive offices are located in Scottsdale, Arizona. Invech Holdings, Inc. has disclosed that it is not an emerging growth company under SEC definitions, as indicated in its Form 8-K filing. The available regulatory disclosures emphasize the trading status of its common stock and its efforts to maintain and enhance quotation and liquidity in the over-the-counter market.

Trading and Market Visibility

In a Form 8-K filed with the SEC, Invech Holdings, Inc. reported that on September 8, 2025, the Financial Industry Regulatory Authority (FINRA) deemed effective a Form 15c2-11 (Form 211) submitted by Glendale Securities, Inc. for the company’s common stock. The effectiveness of this Form 211 allows Glendale Securities, Inc. to resume publishing quotes for IVHI in an over-the-counter quotation medium. The company describes this as a significant step that increases the visibility and liquidity of its common stock in the public market.

Invech Holdings, Inc. states in the same filing that it continues to work with its partners to further its presence in the market and to provide more transparent and timely information to its shareholders and the broader investment community. This focus on quotation eligibility and disclosure practices is central to the company’s current public-market profile as reflected in its SEC reports.

Regulatory and Corporate Framework

As an SEC-reporting company incorporated in Nevada, Invech Holdings, Inc. operates within the U.S. public-company regulatory framework. Its Form 8-K disclosures reference Section 13(a) of the Securities Exchange Act of 1934 and standard SEC rules regarding written communications and pre-commencement communications, indicating that it follows the typical reporting structure for U.S. issuers whose securities are quoted over the counter.

The company’s recent Form 8-K emphasizes Section 8 – Other Events, using that section to inform the market about changes to its quotation status and related developments affecting trading in its common stock. This suggests that, based on available information, a key focus of Invech Holdings, Inc.’s public disclosures is the status and accessibility of its shares in the OTC market rather than detailed operational or segment information.

Information Limitations

Publicly available excerpts from recent SEC filings primarily address the company’s legal identity, jurisdiction of incorporation, trading symbol, quotation venue, and the effectiveness of Form 211. These filings do not provide detailed descriptions of the company’s industry, sector, operating segments, or specific business activities. As a result, any characterization of its business model, products, services, or target markets beyond what is explicitly stated in the filings would be speculative.

Investors and researchers reviewing IVHI should therefore treat the current regulatory disclosures as a source of information on corporate status, trading eligibility, and reporting framework, while recognizing that additional documents would be required to gain a fuller understanding of Invech Holdings, Inc.’s underlying operations or strategic focus.

Role of Form 15c2-11 (Form 211) for IVHI

The Form 8-K filed by Invech Holdings, Inc. highlights that FINRA’s determination that the Form 211 is effective enables a market maker, Glendale Securities, Inc., to resume publishing quotations for IVHI. Under SEC and FINRA rules, this process is central to the ability of a broker-dealer to quote a security in the OTC market. Invech Holdings, Inc. characterizes the effectiveness of Form 211 as an important development for enhancing the visibility and liquidity of its common stock.

By emphasizing the Form 211 effectiveness and the resumption of published quotes, the company signals that access to quotation and trading in the OTC market is a key consideration for its shareholders and potential investors. The company also notes its intention to provide more transparent and timely information, aligning its disclosure practices with the expectations of participants in the over-the-counter marketplace.